Evidence map›Paper›PMID 35035936›Full record

ArticleClinical kidney journal2022

Serum anti-CRP antibodies differentiate etiology and predict relapse in acute tubulointerstitial nephritis.

Jun-Wen Huang, Tao Su, Ying Tan, Jin-Wei Wang, Jia-Wei Tang, Su-Xia Wang, Gang Liu, Ming-Hui Zhao, Li Yang

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. The Role of Anti-mCRP Autoantibodies in Lupus Nephritis.Kidney diseases (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jun-Wen HuangDepartment of Medicine, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.ORCID https://orcid.org/0000-0003-1393-6521
Tao SuDepartment of Medicine, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Ying TanDepartment of Medicine, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Jin-Wei WangDepartment of Medicine, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.ORCID https://orcid.org/0000-0003-0128-8408
Jia-Wei TangDepartment of Medicine, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Su-Xia WangDepartment of Medicine, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Gang LiuDepartment of Medicine, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Ming-Hui ZhaoDepartment of Medicine, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Li YangDepartment of Medicine, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcute tubulointerstitial nephritis (ATIN) is a common cause of acute kidney injury with various etiologies. It has been shown that autoimmune-related ATIN (AI-ATIN) has a higher recurrence rate and a greater likelihood of developing into chronic kidney disease compared with drug-induced ATIN, yet misdiagnosis at renal biopsy is not uncommon.

methodsPatients who were clinicopathologically diagnosed as ATIN from January 2006 to December 2015 in Peking University First Hospital were enrolled. Clinical, pathological and follow-up data were collected. Serum samples on the day of renal biopsy were collected and tested for anti-C-reactive protein (CRP) antibodies. CRP and its linear peptides were used as coating antigens to detect antibodies. Statistical analysis was used to assess the diagnostic value of the antibodies.

resultsAltogether 146 patients were enrolled. The receiver operating characteristic-area under the curve of the anti-CRP antibody for the identification of late-onset AI-ATIN was 0.750 (95% confidence interval 0.641-0.860, P < 0.001) and the positivity was associated with ATIN relapse (adjusted hazard ratio = 4.321, 95% confidence interval 2.402-7.775, P < 0.001). Antibodies detected by CRP linear peptide 6 (PT6) were superior with regard to differentiating patients with AI-ATIN, while antibodies detected by peptide 17 (PT17) could predict ATIN relapse. Antibodies detected by these two peptides were positively correlated with the severity of tubular dysfunction and pathological injury.

conclusionsSerum anti-CRP antibody could be used to differentiate late-onset AI-ATIN and predict relapse of ATIN at the time of renal biopsy. The CRP linear peptides PT6 and PT17 could be used as coating antigens to detect anti-CRP antibodies, which may provide more information for the clinical assessment of ATIN.

Indexed as

acute kidney injuryacute tubulointerstitial nephritisautoantibodyC-reactive proteinrelapse

Identifiers

PMID35035936
PMCPMC8757425
OpenAlexW3180134660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.